PamGene is active in the area of diagnostics research and is in the process of developing clinical biomarkers for therapy response. There is an urgent need to properly predict clinical response to checkpoint inhibitor therapy. In a multi-center effort, we presented a landmark poster at this year’s American Society of Clinical Oncology (ASCO) annual Meeting, held in Chicago, from June 1-5, 2018. We showed that the PamChip blood test can serve as a rapid predictive liquid biomarker test to stratify patients prior to immunotherapy, by measuring kinase activity in patients’ blood prior to therapy start. We are proud and excited to announce that the validation study is currently underway. Please contact us to discuss these new data and the implications for the field.
Session: Melanoma/Skin Cancers (Subtrack: Biomarkers/Epidemiology/Outcomes)Monday, June 4, 2018, Abstract 9579
Blood-based multiplex kinase activity profiling as a predictive marker for clinical response to checkpoint blockade in advanced melanoma.
For more information about the Poster please contact:
- Dianne van den Heuvel (dvdheuvel@pamgene.com)
For follow-up after the ASCO meeting, please contact:
- John Groten (jgroten@pamgene.com)
- Rinie van Beuningen (rvbeuningen@pamgene.com)
- Kristiane Schmidt (kschmidt@pamgene.com)
